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N-Acetyltransferase Phenotype and Risk
in Urinary Bladder Cancer: Approaches
in Molecular Epidemiology.
Preliminary Results in Sweden and
Denmark
by G. M. Lower, Jr.,* T. Nilsson,t C. E. Nelson,t
H. Wolf,t T. E. Gamsky,* and G. T. Bryan*
A variable but often significant proportion of urinary bladder cancer in urban areas can be attributed
to occupational and cultural (cigarette smoking) situations associated with exposures to various
arylamines. The variable N-acetylation ofcarcinogenic arylamines by human hepatic enzyme systems, the
known genetic regulation and polymorphic distribution ofthis enzyme activity in humans, and the known
enhanced susceptibility ofindividuals with the genetically-distinct "slow acetylator" phenotype to various
arylamine toxicities, has prompted examination of possible correlations between N-acetyltransferase
phenotype and urinary bladder cancer risk in rural and urban populations. In this context, N-acetylation
is viewed as a component of detoxication pathways with respect to arylamine bladder carcinogenesis.
In preliminary utilizations of this approach, a population of urban urinary bladder cancer patients
from Copenhagen, Denmark displayed a 13% excess (p = 0.065) of individuals with the slow acetylator
phenotype (46/71 = 64.8%) when compared to a Danish control population (38/74 = 51.4%). These data
are consistent with the possibility that arylamines may play an etiological role in bladder cancer in this
locale and that slow acetylator individuals may be at higher relative risk (1.74) than rapid acetylator
individuals. As 95% of patients reported histories of smoking, it was not possible to isolate and examine
smoking factors.
In contrast, a population of rural urinary bladder cancer patients from Lund, Sweden, where bladder
cancer incidence (20/100,000) (1971) is lower than in Copenhagen (43.8/100,000) (1968-72), no difference
in slow acetylator distribution was observed between bladder cancer (80/115 = 69.6%) and Swedish
control (79/118 = 66.9%) populations, indicating a relative lack of involvement of arylamines in the
etiology of rural bladder cancer.
Populations of "spontaneous" bladder cancer patients would be expected to contain variable portions
ofdisease related to arylamine exposure and would be less likely to display a detectable correlation than
would an industrial population with documentable arylamine exposure. Consequently, confirmation of
this hypothesis is being pursued by examination of industrial populations in an effort to obtain an
empirical estimate of relative risk for slow and rapid acetylator phenotypes. These studies involve
exposure-matched workmen both with and without bladder cancer.
Introduction by Rehnin 1895 (1), the induction ofbladder cancer
in dogs following administration of 2-amino-
Since the initial clinical observations of bladder naphthalene by Hueper in 1938 (2), and the analyti-
cancer victims in the German chemical dye industry cal epidemiological investigations ofbladder cancer
risk within the British dye industries by Case in
* Department of Human Oncology, University of Wisconsin 1953 (3), considerable direct evidence has been ac-
Center for Health Sciences, Madison, Wisconsin 53706. cumulated to implicate arylamines and metaboli-
t Department of Urology, University Hospital, Lund, Swe- cally related aryl nitrogen compounds in the genesis den. of human ary bladdercands the urnary t Department of Urology, Hvidovre University Hospital, of human urinary bladder cancer. Thus, urinary
Copenhagen, Denmark. bladder cancer is recognized as the first human
April 1979 71neoplasm for which precisely-defined chemicals
were suggested as causal agents and for which
chronic exposure to a variety of occupational and
environmental chemicals was suggested as a deter-
mining factor in a high percentage of disease inci-
dence (4, 5).
Those arylamines posing established car-
cinogenic hazard to humans include 2-amino-
naphthalene, 4-aminobiphenyl, 4,4'-diamino-
biphenyl, and 4-nitrobiphenyl utilized in various in-
dustrial processes (4, 5) (Fig. 1). Such arylamines
have found use as reagents in the preparation of
various textile and hair dyes and plant pigments, as
antioxidants in the preparation of rubber for the
manufacture of tires and cables, and as curing
agents in the preparation of various plastics. Simi-
larly, a number of arylamines, such as 3,3'-di-
chlorobenzidine and 4,4'-methylene bis(2-chloro-
aniline) utilized as curing agents in the preparation
ofpolyurethane elastomers, are potent bladder car-
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FIGURE 1. Urinary bladder carcinogens shown to represent
human hazard.
cinogens in rodent or dog model systems and it is
probable that these agents have human carcinogenic
potential (6, 7). Indeed, the widespread industrial
use ofcarcinogenic arylamines has made it apparent
that the epidemiology of occupational bladder
cancer is for all practical purposes synonymous
with the epidemiology of arylamine-induced can-
cers (6).
Estimations of the magnitude of occupational in-
volvement in bladder cancer incidence have ranged
from 10 to 50% (8), although these values are
dynamic and dependent on local environments. For
example, epidemiologic case control investigations
conducted in the metropolitan Boston area indicate
that 15-20% ofbladder cancers can be attributed to
occupational exposures (9), whereas in the met-
ropolitan area of Leeds, England, occupational in-
volvement may be as high as 30% (1O, Ii), with both
areas displaying noteable increases in mortality
rates over the past 30 years. Accordingly, a number
of high risk occupations have been identified, in-
cluding chemical, dye, textile, and rubber workers,
painters, and hairdressers (4, 9).
Similarly, case control investigations indicate
that a variable portion of human bladder cancers
can be attributed to exposures to cigarette smoke,
the magnitude of involvement reaching 35-40% in
metropolitan Boston, and perhaps even higher in
metropolitan areas of Canada (12, 13). Common
ground is provided here by virtue ofthe presence in
tobacco smoke condensate of various arylamines
including the established human bladder carcino-
gen, 2-aminonaphthalene (14), metabolites ofwhich
have reportedly been identified in the urine ofheavy
smokers (15). In view of these considerations, it
seems reasonable to suggest that in the metropolitan
Boston area, for example, perhaps 50-60% of
human bladder cancers can be attributed to occu-
pational and cultural situations associated with ex-
posures to various arylamines, many of which rep-
resent established human carcinogens.
It is generally accepted that the carcinogenic
arylamines represent latent biological arylating
agents which require metabolic transformation to
chemically reactive metabolites (electrophiles) by
enzyme systems of the susceptible host, and that
the substrate specificity and functional capacity of
enzyme systems involved in activation and detox-
ication often play major roles as determinants of
species and tissue susceptibility (16-18). In the dog,
for example, susceptibility to bladder carcin-
ogenesis can be correlated with the functional
capacity of endoplasmic reticulum-associated
mixed function oxygenase enzyme systems requir-
ing NADPH and molecular oxygen and involved in
N-hydroxylation (activation) to proximate N-
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readily N-hydroxylated (e.g., 2-aminonaphthalene)
display potent carcinogenic activity in the dog,
while closely related arylamines which are not
readily N-hydroxylated (e.g., 1-aminonaphthalene)
are essentially devoid of carcinogenic activity in
this species (19, 20). Similarly, species such as the
guinea pig, which are deficient in the capacity to
N-hydroxylate aryl nitrogen compounds, are re-
fractory to such insult (21).
Such clean simple relationships are, however,
often overridden and obscured from view by com-
peting metabolic factors. With the arylamines, this
results from the interrelationships of metabolic
pathways involved in arylamine activation and de-
toxication, and the conversion of arylamines to dif-
fering ultimate electrophiles with differing tissue
specificities and toxicities. Thus, while the proxi-
mate carcinogenic metabolites involved in urinary
bladder carcinogenesis are evidenced to be non-
acetylated N-hydroxyarylamines (arylhydroxyl-
amines), the proximate carcinogenic metabolites in-
volved in hepatocarcinogenesis are evidenced to be
acetylated N-hydroxylarylacetamides (arylhydrox-
amic acids), with both of these proximate car-
cinogenic metabolites being derived from
arylamines and arylacetamides by virtue of parallel
divergent metabolic pathways (Fig. 2) (22, 23).
For example, administration of a variety of car-
cinogenic arylamines to dogs has resulted in the
formation of only urinary bladder tumors, the liver
apparently being refractory in keeping with an ap-
parent total deficiency in the capacity to N-
acetylate arylamines, observations providing an in-
dication that N-acetylation is not required for blad-
der carcinogenesis (23). In contrast, administration
of structurally analogous carcinogenic aryl-
acetamides to dogs has resulted in the unequivocal
formation of both urinary bladder tumors and
hepatomas, with susceptibility to bladder carcino-
genesis being correlated with the substrate specific-
ity of arylacetamide deacetylase enzyme systems,
observations providing an indication that removal
of the acetyl group is required for bladder carcino-
genesis (24).
In other words, N-hydroxylating enzyme systems
can be viewed as components of activation path-
ways with respect to both arylamine bladder car-
cinogenesis and arylacetamide hepatocar-
cinogenesis, while N-acetyltransferase enzyme
systems can be viewed as components ofactivation
pathways with respect to arylamine hepatocar-
cinogenesis and as components of detoxication
pathways with respect to arylamine bladder car-
cinogenesis. Similarly, arylacetamide deacetylase
enzyme systems can be viewed as components of
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FIGURE 2. Proposed parallel pathways for the metabolic activa-
tion of arylamines and arylacetamides to electrophilic reac-
tants involved in urinary bladder and hepatocarcinogenesis.
detoxication pathways with respect to aryl-
acetamide hepatocarcinogenesis and as components
of activation pathways with respect to aryl-
acetamide bladder carcinogenesis. These concepts
appear to be generally applicable to mammalian
systems with the potentially rate-limiting role of a
given enzyme system being a relative one, depen-
dent on species-specific metabolic capabilities (24).
Thus, it is probable that activating and detoxifying
enzyme systems might also act as partial determi-
nants of human susceptibility to bladder car-
cinogenesis by arylamines, and it becomes impor-
tant to clarify the role of these metabolic factors
from a human frame of reference.
For example, in the human, hepatic N-
acetyltransferase enzyme systems are subject to
Mendelian genetic regulation as an autosomal re-
cessive trait, resulting in an approximate 50:50
polymorphic distribution in North American white
populations, with individuals displaying either the
".,.slow acetylator" phenotype or the "rapid
acetylator" phenotype (25, 26). At present, the lit-
erature contains a number ofentries demonstrating
April 1979 73the role of N-acetyltransferase phenotype as a par-
tial determinant of susceptibility to the dose-related
toxicities of various acetylable nitrogen compounds
(26-37) (Table 1). In the case of peripheral
neuropathies associated with isoniazid (27, 28),
phenelzine (29), hydralazine (30), and sali-
cylazosulfapyridine (31) exposures, and as would be
expected for bladder cancer associated with
arylamine exposures, it is the genetically distinct
slow acetylator phenotype demonstrating enhanced
susceptibility to toxicity, due in part to the de-
creased ability ofthese individuals to detoxify these
chemicals by N-acetylation. As might be antici-
pated, the converse is also true. In the case of
hepatotoxicity which appears to be elicited by
acetylated metabolites (32) associated with
isoniazid exposure (33), it is the genetically distinct
rapid acetylator phenotype demonstrating enhanced
susceptibility (34).
Investigation of the in vitro acetylation of
arylamines by human liver cytosol has indicated
that the carcinogenic arylamines such as 2-
aminonaphthalene and 4-aminobiphenyl display a
strong affinity for this polymorphically distributed
enzyme system, and, moreover, liver cytosol from
rapid acetylator phenotypes effected an 8 to 12
times greater acetylation rate in vitro than that ob-
served with liver cytosol from slow acetylator
phenotypes (38). These observations again suggest
that rapid and slow acetylator phenotypes might
show differential susceptibility to arylamine car-
cinogenesis in parallel with their differential ability
to detoxify arylamines by N-acetylation.
Insofar as individuals of the slow acetylator
phenotype would be expected to be at relatively
greater risk to arylamine carcinogenesis, one would
expect a population ofbladder cancer patients (pro-
vided some portion of patients have arylamine-
induced disease) to display a greater percentage of
slow acetylator phenotypes than would a control
cancer-free population. The results of preliminary
efforts to examine this hypothesis in populations of
Danish and Swedish urinary bladdercancer patients
comprise the subject ofthis report.
Methods
Patient and Control Populations
Patient populations consisted of individuals with
histologically-confirmed papillomas and invasive
carcinomas of the urinary bladder. The Swedish
population was derived from the rural area sur-
rounding Lund, Sweden and was represented by
115 patients admitted to the Department of Urology
at University Hospital. Age-adjusted incidence
rates for the counties in this area ranged from 15 to
20 cases/100,000 for 1971 (39) and are similar to the
incidence rate of 21.2 per 100,000 observed in rural
Denmark for the years 1968-72 (40).
In contrast, the Danish population was derived
from the urban center ofCopenhagen, Denmark and
was represented by 71 patients admitted to the De-
partment of Urology at Hvidovre University Hos-
pital. The age-adjusted incidence rate for this urban
area was estimated at 43.8 per 100,000 for the years
1968-72 and has shown a 100% increase since 1948
(40).
Control populations were derived from healthy
hospital personnel and hospital patients admitted
for non-malignant disease and were represented by
118 individuals from University Hospital in Lund
and 74 individuals from Hvidovre University Hos-
pital in Copenhagen. Separate nationality-matched
control groups were required in each geographic
area due to variability in the percentage of slow
acetylator phenotypes with genetic background,
although, as an autosomal recessive trait, N-
acetyltransferase phenotype is not linked to sex and
development age (25).
Table 1. N-Acetyltransferase phenotype as a determinant of human susceptibility to the dose-related toxicities of
polymorphically-acetylated nitrogen compounds.
Polymorphically acetylated Dose-related toxicities
nitrogen compounds (susceptible phenotype) References
Isoniazid Peripheral neuropathies (S) Hughes (27)
Isoniazid Peripheral neuropathies (S) Devadatta (28)
Pheneizine Drowsiness, dizziness, nausea (S) Evans (29)
Hydralazine Peripheral neuropathies (S) Perry (30)
(Lupus erythromatosus-like syndrome)
Salicylazosulfapyridine Cyanosis, hemolysis, and reticulocytosis (S) Das (31)
(Sulfapyridine)
Isoniazid Hepatitis (R) Mitchell (34)
Procainamide Systemic lupus erythromatosus (S) Woosley (3S)
'Spontaneous" systemic Lupus Reidenberg (36)
Erythromatosus (S)
? Diabetic neuropathy (S) McLaren (37)
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The method employed for determination of
human N-acetyltransferase phenotype was essen-
tially that of Weber and Brenner (41). Patients were
instructed not to eat after midnight or to drink fluids
after 7 AM of the day of the test. At 9 AM, the
subjects were administered 10 mg/kg commercially
available sulfamethazine (free acid) orally as a
slurry in 2-3 oz of water. After 11 AM, patients
were permitted to eat and drink as usual. The blad-
der was voided of urine at noon and urine was then
retained until collection of blood and urine speci-
mens. At 1:30 PM (4.5 hr after sulfamethazine in-
gestion), samples of blood from a venipuncture and
urine were collected and refrigerated, following re-
moval of0.1 ml aliquots of each which were placed
upon filter paper discs (Whatman No. 3) and air
dried for analysis.
Free (unacetylated) and total (unacetylated and
acetylated) sulfamethazine on filter paper discs
were quantitated by a micromodification of the
Bratton-Marshall procedure as described by Weber
and Brenner (41) and phenotypic categorization was
accomplished by plotting percent acetylated sul-
famethazine in blood versus urine, a manipulation
yielding two distinct nonoverlapping populations
(Fig. 3).
Statistical p values were determined by the exact
method for 2 x 2 contingency tables and relative
risk was calculated as described by Armitage (42).
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FIGURE 3. Distribution of N-acetyltransferase phenotype in a
urinary bladder cancer population from Copenhagen, Den-
mark.
Results
The results of efforts to determine the N-
acetyltransferase phenotype distribution in bladder
cancer and control populations from Denmark and
Sweden are presented in Table 2. Individuals in
these studies could be readily catagorized as slow
and rapid acetylators with slow acetylators dem-
onstrating an average acetylsulfamethazine content
of22.5% in blood and 59.6% in urine and with rapid
acetylators demonstrating an average acetylsul-
famethazine content of57.5% in blood and 85.9% in
urine.
The slow acetylator phenotype in an urban con-
trol population from Copenhagen, Denmark was
found to comprise 51.4% (38/74) while in an urban
bladder cancer population from the same area, the
slow acetylator phenotype was found to comprise
64.8% (46/71) (Fig. 3). With a one-sided test, the
excess of 13.4% slow acetylators in the bladder
cancer population is characterized by an exact p-
value of 0.065, and based upon these data the cal-
culated relative risk for slow acetylator phenotypes
is 1.74. Within the bladder cancer population,
95.7% (22/23) of rapid acetylators and 95.5% (42/44)
of slow acetylators reported histories of cigarette
smoking. In this population, only three patients
were nonsmokers, and no information was available
on four patients. Similarly, the percent heavy
smokers (>1 pack/day, 20%) and light smokers (<I
pack/day, 76%) was similar for both rapid and slow
acetylators, and it was not possible to separate out
smoking factors.
In contrast, the slow acetylator phenotypes in a
rural control population from Lund, Sweden was
found to comprise 66.9% (79/118), and in a rural
bladder cancer population from the same area, the
slow acetylator phenotypes comprised 69.6% (80/
115) (Table 2). This differential of2.7% is not statis-
tically significant, nor do the values of both control
and bladder cancer populations differ from control
values of 67% previously observed for U. S. Scan-
dinavians (43).
Discussion
The finding ofan excess ofindividuals ofthe slow
acetylator phenotype within an urban bladder
cancer population from Denmark suggests that
arylamines may play a role in disease etiology in
this locale and that slow acetylator individuals may
be at higher risk to arylamine-induced bladder
cancer. Estimations of the percent of urinary blad-
der cancer in Copenhagen attributable to occupa-
tional and smoking factors are presently unavail-
able, although the high and increasing incidence
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ASM in
ASM in urine, Slow
blood, % % acetylator p value
Population Number (mean ± SDY) (mean ± SDY' phenotypes, % (relative risk)
Denmark Control
(urban) Slow phenotypes 38 22.8 ± 8.4 62.7 ± 7.2
51.4
Control
Rapid phenotypes 36 61.1 t 10.9 86.9 +5.5
0.065
Bladder cancer
Slow phenotypes 46 27.1 ± 7.8 54.9 ± 10.8 (1.74)
64.8
Bladder cancer
Rapid phenotypes 25 60.8 t 7.2 86.5 t 4.0
Sweden Control
(rural) Slow phenotypes 79 20.6 ± 8.9 58.0 t 8.4
66.9
Control
Rapid phenotypes 39 56.6 t 13.3 84.8 + S.5 5
N.S.
Bladder cancer
Slow phenotypes 80 19.6 t 5.6 62.9 t 7.3
69.6
Bladder cancer
Rapid phenotypes 35 51.4 t 13.2 85.5 t 5.2
ASM = acetylsulfamethazine.
rate in this area (40) and the known involvement of
occupational and smoking factors in urban areas of
the U. S. (44) indicate that arylamines are likely to
play some finite role.
In contrast, the similar distribution of individuals
ofthe slow acetylator phenotype in control and uri-
nary bladder cancer populations from rural Sweden
may be interpreted as negative data or as a relative
lack of involvement ofarylamines in the etiology of
rural bladder cancer. Indeed, multifactorial chemi-
cal hypotheses, not involving occupational
arylamines, have been presented specifically to ap-
proach the etiology ofthose urinary bladder cancers
presently referred to as "spontaneous" and in those
relatively rural areas providing a more generalized
"background" mortality rate (45).
The high percentage of slow acetylator
phenotypes in control Swedish populations points
out a limitation of this approach, insofar as high
control values would make more difficult the detec-
tion ofa significantly higher value in urinary bladder
cancer populations. Similarly, these observations
point out the variability of N-acetyltransferase
phenotype distribution as a function of genetic
background (43). Thus, for example, the percentage
of individuals of slow acetylator phenotype ranges
from 50% in North American white populations to
70% in Israeli populations, while in oriental popula-
tions this recessive trait is much less frequent and
appears in only 5-15% of individuals (43).
With quantitative involvement of arylamines in
disease etiology one might expect about 80% of in-
dividuals suffering arylamine toxicities to display
the slow acetylator phenotype (30, 31), with the
percent slow acetylator phenotype in a given blad-
der cancer population being some function of the
percent of patients with arylamine-induced disease.
Forexample, in North American white populations,
the slow acetylator phenotype observed in bladder
cancer populations might be expected to range be-
tween 50 and 80%, depending on whether arylamine
involvement ranges from negligible to essentially
quantitative. Given this situation, it can be esti-
mated by direct proportion that the detection of a
15% excess of slow acetylator phenotypes in a
bladder cancer population would require the in-
volvement of arylamines to the extent of 40% or
more. In other words, populations of "spontane-
ous" bladder cancer patients would be less likely to
show such a correlation than would an industrial
population with documentable arylamine exposure.
Consequently, confirmation of this hypothesis
will require examination of industrial bladder
cancer populations in an effort to obtain an empiri-
cal estimate of relative risk for slow and rapid
acetylator phenotypes. Provided that this aryl-
amine-specific human enzyme system plays a suffi-
ciently rate-limiting role in arylamine carcino-
genesis, such investigations ought allow assessment
of the feasibility of utilizing this approach in the
Environmental Health Perspectives 76determination of high and low risk individuals
within high risk environments, and assessment of
the relative importance of internal and external
factors in the determination ofoverall relative risk.
In this respect, enzyme systems involved in
arylamine N-hydroxylation are equally likely to
serve as partial determinants of human susceptibil-
ity to arylamine-induced urinary bladder cancer. It
is important to note here that proximate N-
hydroxyarylamines involved in bladder car-
cinogenesis and proximate N-hydroxyaryl-
acetamides involved in hepatocarcinogenesis, while
more highly carcinogenic than their respective par-
ent arylamines and arylacetamides, are not par-
ticularly chemically reactiveper se and may require
further metabolic activation to electrophilic forms.
A number of detailed studies now indicate that a
second enzyme-mediated process required in the
metabolic activation of hepatocarcinogenic
arylacetamides involves the esterification of the
N-hydroxyarylacetamides (16, 46). Furthermore, in
the case ofsulfate conjugation, there is a close cor-
relation of the activity of soluble sulfotransferase
enzyme systems with the susceptibility of experi-
mental animals to hepatocarcinogenesis (47). By
analogy, one might expect that esterification of
N-hydroxyarylamines would give rise to elec-
trophilic metabolites. Indeed, the N-O-glucuronide
conjugate of N-hydroxy-2-aminofluorene, when
generated in vitro, represents an extremely potent
electrophile (48, 49), although such compounds
have yet to be demonstrated as in vivo metabolites.
Alternatively, the N-glucuronides of N-hydroxy-
arylamines (Fig. 2), which are readily formed by
dog and human hepatic microsomal enzyme sys-
tems, undergo hydrolysis at the acidity of urine to
yield similar electrophilic reactants (50).
Thus, while the exact identity ofthe ultimate car-
cinogenic metabolite(s) involved in the initiation of
bladder carcinogenesis remains uncertain, it seems
reasonable to expect that any enzyme system in-
volved in the further metabolic activation of N-
hydroxyarylamines might serve as a potential de-
terminant of bladder susceptibility. Indeed, full as-
sessment of relative risk to arylamine car-
cinogenesis might be expected to require assess-
ment ofexternal factors such as age of initial expo-
sure, relative exposure levels, and duration of ex-
posure; and assessment of internal factors such as
the relative ratio ofthe functional capacities ofacti-
vation pathways to detoxication pathways.
The basis for these approaches to the assessment
ofthe role ofinternal factors in the determination of
relative risk is derived from the examination of
chemical carcinogenesis in experimental animal
models and rests upon the observation and realiza-
tion that many chemical carcinogens, including the
arylhydrocarbons and arylamines, are subject to
host enzyme-mediated activation and detoxication
processes, and that the substrate specificity and
functional capacity of these enzyme systems often
play major roles as determinants of species and tis-
sue susceptibility (16, 17, 47).
In the examination ofcausality and relative risk in
the human population, this approach is exemplified
by recent successful efforts to correlate differential
activities of arylhydrocarbon hydroxylase (AHH,
an enzyme system involved in arylhydrocarbon ac-
tivation processes) with differential human suscep-
tibility to cigarette smoke (presumably arylhydro-
carbon)-induced lung and laryngeal cancer (51, 52).
Such approaches represent efforts to make
molecular level observations demonstrating differ-
entials in the specificity and functional capacity of
host-mediated activation and detoxication pro-
cesses that are analogically and spatiotemporally
consistent with both cellular and organismal level
observations of risk, an approach for which the
term "'molecular epidemiology" has been coined
(53). Thus, molecular epidemiology concerns itself
with causal disease processes including those pro-
cesses involved in the emergence of environmental
hazard, those processes involved in the environ-
mental dynamics of causal agents, and those pro-
cesses involved in causal agent-host interactions
which underly the initiation of effectual disease
processes (45).
With respect to urinary bladder cancer causality,
these approaches have included: (1) the identifica-
tion of causal agents in high risk environments as
exemplified by the identification of carcinogenic
arylamines in situations involving occupational ex-
posures (3, 4) and the identification of 2-amino-
naphthalene in cigarette smoke (14); (2) the identifi-
cation of causal agents in biologic fluids derived
from the potential host as exemplified by the iden-
tification of diazotizable arylamines in the urine of
exposed workmen (4) and the identification of 2-
nitrosonaphthalene in the urine of heavy smokers
(15); and (3) the identification of host metabolic
factors involved in the attenuation of causal agent-
host interactions and the correlation ofdifferentials
in rates of activation and detoxication with relative
risk as exemplified by the present report and reports
of an excess activity of arylhydrocarbon hydroxy-
lase among individuals with previous smoking his-
tories and lung cancer (51, 52).
Thus, these approaches in molecular epidemiol-
ogy represent efforts to make empirical observa-
tions of differential molecular-level attenuations of
causal agent-host interactions that are analogically
consistent with epidemiologic observations of risk
April 1979 77at the organismal level, and represent efforts to de-
termine the true propositions ofone level oforgani-
zation and observation (organismal) by the making
of analogical deductions based upon observations
derived from underlying levels of organization
(molecular) (45, 54). Insofar as the majority of
human epithelial cancers bear evidence ofchemical
etiology (45, 53), it is reasonable to extend these
modes of inquiry to the human situation.
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